Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces the successful completion of its Medical Device Single Audit Program (MDSAP) recertification audit, renewing certifications for Europe, the United States, Canada and Brazil.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces its commitment to expand the availability of RefluxStop and training of new centers across Europe and the UK in view of the recent announcement to withdraw the LINX™[1] Reflux Management System[ ]from the European market effective March 31, 2026, as reported across many media outlets.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the U.S. Food and Drug Administration (FDA) has supplied its review of the final PMA Module 3 submission for RefluxStop® and provided favorable feedback, as assessed by the company.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces RefluxStop® was met with great enthusiasm and positive feedback among 600+ attendees at the 2025 American Foregut Society (AFS) Annual Meeting, further accelerating US pre-launch readiness.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 09 September 2025 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees.

Implantica AG (publ.), ett medicintekniskt företag som ligger i framkant när det gäller att introducera avancerad teknik i kroppen, meddelar att bolaget den 09 september 2025 genomförde en riktad nyemission av aktier utan betalning för att tillgodose delar av aktieincitamentsprogrammet för nyckelpersoner.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces its strategy to produce 10,000 RefluxStop® devices in preparation for the expected, substantial demand from the U.S. market, following FDA PMA approval.

Implantica AG (publ), ett medicintekniskt företag som ligger i framkant när det gäller att introducera avancerad teknik i kroppen, inklusive den unika produkten RefluxStop™ för behandling av sura uppstötningar, ett behandlingsområde med 1 miljard drabbade, tillkännager sin strategi att tillverka 10 000 RefluxStop®-enheter som förberedelse för den förväntade stora efterfrågan från den amerikanska marknaden efter FDA:s PMA-godkännande.

Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces completion and initial validation of a new RefluxStop® U.S. production tool as Implantica prepares for quickly increasing demand from the U.S. and markets worldwide, pending FDA approval.